Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 07 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 44 Beijing 38 Shanghai 26 Fuzhou 20 Hangzhou 18
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou44 Beijing38 Shanghai26 Fuzhou20 Hangzhou18
All 57 locations
Target enrolment
to

Trials with a site in Hangzhou

18 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Ningbo No.2 Hospital
Early Phase 1
156
Hangzhou, Ningbo
2026-03-31
Recruiting
Sir Run Run Shaw Hospital
Not applicable
33
Hangzhou
2025-12-01
Active, closed
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2024-09-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
600
Hangzhou
2024-02-05
Active, closed
Hoffmann-La Roche
Phase 3
687
Baoji, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2023-09-14
Recruiting
Zhejiang Cancer Hospital
Phase 2
35
Hangzhou
2023-07-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
140
Hangzhou
2023-03-01
Active, closed
AstraZeneca
Phase 3
214
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan
2023-02-15
Recruiting
OriCell Therapeutics Co., Ltd.
Phase 1/2
105
Beijing, Changsha, Changchun, Chengdu, Hangzhou, Lishui, Shanghai
2022-12-15
Active, closed
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou
2022-03-28
Recruiting
Zhejiang University
Phase 1
72
Hangzhou, Zhengzhou
2022-02-21
Active, closed
Hoffmann-La Roche
Phase 3
342
Anhui, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-03-12
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Active, closed
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2018-11-30
Active, closed
AstraZeneca
Phase 3
1,324
Beijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou
2017-10-11
Active, closed
MedImmune LLC
Phase 2
433
Hangzhou, Nanjing, Shanghai
2015-10-19
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 07 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies with a site in Hangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Hangzhou?

7 of the 18 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hangzhou), 18 studies
PhaseStudiesRecruitingShare
Phase 37138.9%
Not applicable3216.7%
Phase 23116.7%
Phase 1/22111.1%
Early Phase 1105.6%
Observational115.6%
Phase 1115.6%

Most active sponsors

Lead sponsors with the most studies (Hangzhou)
Lead sponsorStudiesRecruiting
AstraZeneca50
Second Affiliated Hospital, Zhejiang University, School of Medicine32
Hoffmann-La Roche20
Akeso11
Ascentawits Pharmaceuticals, Ltd10
MedImmune LLC10
Ningbo No.2 Hospital10
OriCell Therapeutics Co., Ltd.11
Sir Run Run Shaw Hospital11
Zhejiang Cancer Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.